14.25
0.19 (1.35%)
| Previous Close | 14.06 |
| Open | 14.06 |
| Volume | 269,758 |
| Avg. Volume (3M) | 720,398 |
| Market Cap | 967,130,176 |
| Price / Earnings (TTM) | 6.85 |
| Price / Earnings (Forward) | 8.70 |
| Price / Sales | 2.68 |
| Price / Book | 1.40 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2026 |
| Profit Margin | 44.79% |
| Operating Margin (TTM) | 20.06% |
| Diluted EPS (TTM) | 2.23 |
| Quarterly Revenue Growth (YOY) | -3.00% |
| Quarterly Earnings Growth (YOY) | -23.20% |
| Total Debt/Equity (MRQ) | 0.90% |
| Current Ratio (MRQ) | 8.73 |
| Operating Cash Flow (TTM) | 122.59 M |
| Levered Free Cash Flow (TTM) | 73.58 M |
| Return on Assets (TTM) | 8.62% |
| Return on Equity (TTM) | 24.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | InMode Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | -1.00 |
|
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 15.35% |
| % Held by Institutions | 72.07% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (UBS, 12.28%) | Hold |
| 16.00 (Canaccord Genuity, 12.28%) | Hold | |
| Median | 16.00 (12.28%) | |
| Average | 16.00 (12.28%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 14.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 06 Nov 2025 | 16.00 (12.28%) | Hold | 14.44 |
| Canaccord Genuity | 10 Oct 2025 | 16.00 (12.28%) | Hold | 15.27 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins |
| 03 Nov 2025 | Announcement | InMode Appoints Michael Dennison as President of North America |
| 30 Oct 2025 | Announcement | InMode to Participate in Upcoming Investor Conferences |
| 09 Oct 2025 | Announcement | InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M |
| 09 Sep 2025 | Announcement | DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |